News

If approved, daridorexant would become the first sleep medication to demonstrate an improvement in sleep and daytime functioning, while keeping a favorable safety profile in adult and elderly patients.

A recent study investigated the natural history of Dravet Syndrome in adults.

In the phase 3 ADVANCE trial, all active treatment arms of atogepant met their primary end point, and the 30-mg and 60-mg doses met all 6 secondary end points with statistical significance.

The director of the Institute for Health, Health Care Policy, and Aging Research at Rutgers University discussed the reasons behind the lack of real-world dementia studies.

Researchers found that taking into account PWA increased total arousal index more than 3-fold.

The SNP-targeting agents showed no evidence of dose response in PRECISION-HD2 and similar results in PRECISION-HD1, though development of SNP3-targeted agent WVE-003 in HD will continue.

Researchers conducted a systematic review of studies reporting on patients with both COVID-19 and stroke and found worse outcomes compared to patients with stroke alone.

Patients treated with NurOwn showed a mean improvement from baseline of 10% in timed 25-foot walk and a 4.9% improvement from baseline on the 9-hole peg test dominant hand.

The PhD candidate at the Barts MS Center in London discussed her study presented at ACTRIMS Forum 2021 that evaluated CPD in patients with relapsing MS.

The PoNS device becomes the first and only medical device cleared in the US for short-term treatment of gait in patients with multiple sclerosis.

The duo from Montefiore Medical Center detailed the reasons why EEGs must remain an interictal part in improving rates of misdiagnosing neonatal seizures.

Here's what is coming soon to NeurologyLive.

Howard Fillit, MD, the founding executive director and chief science officer, Alzheimer's Drug Discovery Foundation, shared his thoughts on the recently published data.

The Adults with SMA Virtual Therapy Program is sponsored by Genentech and the Dhont Family Foundation.

Researchers analyzed levels of sGFAP in participants from the N-MOmentum study that assessed inebilizumab (Uplizna; Viela Bio) in relapsing-remitting MS.

Researchers observed improvements in motor and respiratory function and biomarkers in the investigational treatment group.

Alise Carlson, MD, a resident at Cleveland Clinic, detailed the reasons for her study evaluating genetic leukodystrophies and their differences to multiple sclerosis at diagnosis.

The triage software yielded a sensitivity and specificity of 59.7% and 91.5%, respectively, for all scans in a study including more than 1000.

Neurology News Network for the week ending March 27, 2021.

The director and founder of the Sleep Centers of Middle Tennessee discussed the misleading nature of the term ‘sleep apnea.’

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 26, 2021.

Behavioral abnormalities, reported from 14 studies, highlighted autistic-like traits and attention and hyperactivity disorders, slightly improving with age in patients with Dravet syndrome.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine outlined the Florida Stroke Registry and its capabilities.

The VBP-LTE study found no evidence of slowed linear growth, insulin resistance, or osteocalcin decreases.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Brian Grosberg, MD.

The Astellas Pharma agent earned an indication for children aged 3 years and older, after its original overactive bladder indication in 2012.

The senior vice president and chief medical officer at Novartis Gene Therapies shared his perspective on the recent clinical trial results for Zolgensma in SMA type 1.

The director of the Montefiore Headache Center discussed recent advances in treating migraine both acutely and preventively.

An overview of the NeurologyLive tweet chat honoring Multiple Sclerosis Awareness Month, featuring highlighted contributions from the medical community.

AC Immune SA is also developing an optimized formulation being tested in mice and non-human primates.